Gemigliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, has emerged as a promising therapeutic option for individuals with type 2 diabetes mellitus. With its unique mechanism of action, favorable efficacy, and safety profile, gemigliptin represents a significant advancement in the management of diabetes.
Understanding Gemigliptin
Gemigliptin belongs to a class of medications known as...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian